US Edition
Novo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say - Novo Nordisk (NYSE:NVO)
- The European Medicines Agency's safety committee concluded in 2025 that semaglutide, used in Ozempic, Wegovy, and Rybelsus, has a very rare risk of causing NAION, a vision-loss condition.
- This conclusion followed a review initiated in December 2023 after studies from Scandinavia and clinical trial data indicated a two-fold increased NAION risk in type 2 diabetes patients using semaglutide.
- Research from the University of Toronto found that older adults with diabetes using GLP-1 receptor agonists had more than twice the likelihood of developing the advanced, vision-threatening form of age-related macular degeneration involving abnormal blood vessel growth, with the risk increasing the longer the medication was used.
- EMA recommended updating product labels to warn about NAION, noting it may affect about 1 in 10,000 people annually, and urged patients with sudden vision loss to seek immediate medical advice.
- These findings triggered lawsuits, including a 2024 US case and a Pennsylvania class action with over 1,000 claimants, and imply that users require monitoring for rare but serious eye complications.
77 Articles
77 Articles
Ozempic Users May Face Higher Risk of a Serious Eye Disease
New research found a link between GLP-1 use in people with diabetes and an elevated chance of wet AMD, which can cause blindness.Fact checked by Nick BlackmerKAREN BLEIER / Staff / Getty Images Wet AMD affects the macula, in the back of the eye, and can lead to blindness.New research found a link between GLP-1 use among people with diabetes and a higher risk of wet neovascular age-related macular degeneration.Neovascular age-related macular dege…
Alternative weight loss drug to be sold in PH soon
MANILA, Philippines — Denmark-based multinational pharmaceutical company Novo Nordisk will make Wegovy, its approved weight-loss treatment for individuals with obesity, available in the Philippines “anytime between the third and fourth quarter” of the year. This will address the “artificial” shortage of Ozempic, another Novo Nordisk drug, which is prescribed for the treatment of type 2 diabetes but has been used off-label as a weight loss medica…
The Spanish Agency for Medicines and Health Products (AEMPS) has reported the risk that patients treated with semaglutide suffer from optical neuropathy.
The Spanish Agency for Medicines and Health Products (AEMPS), an organization integrated into the Spanish Ministry of Health, warned about the risks of non-arterritic anterior ischemic optic neuropathy (NOIANA) - commonly known as sudden blindness - by using drugs to treat type 2 diabetes or obesity such as, for example, Ozempic.Read more]]>
Coverage Details
Bias Distribution
- 36% of the sources lean Left
To view factuality data please Upgrade to Premium
